cas 101990-69-6|| where to buy 4-Pyridinemethanol,2,6-dichloro-

Nom du produit:4-Pyridinemethanol,2,6-dichloro-

IUPAC Name:(2,6-dichloropyridin-4-yl)methanol

Unité d'emballage	Stock disponible	Prix($)
CM101492-10g	in stock	ƴƴȯ
CM101492-25g	in stock	ȅŪȅ
CM101492-100g	in stock	ƃŪƃ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 101990-69-6 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:101990-69-6; Formule moléculaire:C6H5Cl2NO; Point de fusion:-; Code SMILES:OCC1=CC(Cl)=NC(Cl)=C1; Densité:1.478g/cm3

: Numéro de catalogue:CM101492; Poids moléculaire:178.01; Point d'ébullition:; N° Mdl:MFCD00052638; Stockage:Store at 2-8°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: ABBV-712; TYK2 is an attractive target for various autoimmune diseases as it regulates signal transduction downstream of IL-23 and IL-12 receptors. Selective TYK2 inhibition offers a differentiated clinical profile compared to currently approved JAK inhibitors. Scientists discovered the clinical candidate ABBV-712 in the optimization of selective TYK2 inhibitors targeting the pseudokinase domain.